ID: MRFR/HC/5800-CR | January 2019 | Region: Global | 175 pages
The myasthenia gravis market is projected to witness a compound annual growth rate of 10.10% during the forecast period (2020-2030). There has been a substantial rise in prevalence of myasthenia gravis in recent years, which led to a sharp increase in treatment demand. Myasthenia gravis (MG) is an autoimmune neuromuscular disorder, its primary impact include decrease in the concentration of AChRs on the muscle endplate membrane. North America and Latin America collectively make the largest contribution to the growth of the global myasthenia gravis market. Meanwhile, Europe and Asia Pacific hold the second and third spot in terms of value.
Myasthenia Gravis Market Overview
This MRFR perspective presents a holistic outlook on the global myasthenia gravis market. It also includes a revenue forecast till 2023 along with a three-year (2015-2018) historical analysis. Market dynamics such as drivers, restraints and opportunities have been thoroughly discussed in the research document. Also, market assessment based on various types of myasthenia gravis (ocular myasthenia gravis, congenital myasthenia gravis, generalized myasthenia gravis, transient myasthenia gravis and others) is also available in the report.
Myasthenia Gravis Market Report Coverage
Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market
GE Healthcare, Alexion Pharmaceuticals, Inc, Novartis AG, Pfizer Inc., Boston Scientific Corporation, CSL Behring, Medtronic Plc., Baxter, Grifols S.A., Shire, Koninklijke Philips N.V., and Valeant Pharmaceuticals International, Inc.
MRFR is committed to deliver a highly accurate market outlook, deep-diving into the crux. This is done by following a systematic and fail-safe research structure. It ensures market sizing and evaluation is conducted with an unbiased viewpoint and presentation of error-free perspective. A combination of primary and secondary research input allows accountability of market findings. For this, a wide variety of research material is amassed, which includes surveys, bites from c-level executives, expert opinion, white paper, SEC filing, paid database services etc. Emphasis is placed on delivering actional market insights though extensive data assessment. In addition, verification of research findings involves undertaking of top-down and bottom-up approaches.
By Diagnosis and Treatment
Frequently Asked Questions (FAQ) :
Myasthenia Gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body.
Myasthenia Gravis Market is expected to exhibit a strong 10.10% CAGR over the forecast period from 2020 to 2030.
Increasing prevalence of neuromuscular disorders and the growing awareness about the disease are the major drivers for the Myasthenia Gravis Market.
Americas accounted for the largest share in the market in 2016.
Leading players in the Myasthenia Gravis Market include Valeant, Piramal Healthcare, and Biogen Inc., among others.
Global Myasthenia Gravis Market: Company Landscape
The global myasthenia gravis market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of the market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although the international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.
Alexion Pharmaceuticals, Inc., is major player in the global myasthenia gravis market. The company is focused on serving patients and families affected by rare diseases through the discovery, development, and commercialization of life-changing therapies. Alexion Pharmaceuticals, Inc., is best known for its development of Soliris, a drug used to treat rare disorders, atypical hemolytic uremic syndrome, and paroxysmal nocturnal hemoglobinuria. In October 2017, FDA Approved Soliris (eculizumab) for the treatment of patients with Generalized Myasthenia Gravis (gMG).
In September 2018, Alexion Pharmaceuticals, Inc. announced positive results from the Phase 3 PREVENT study of Soliris (eculizumab) in patients with anti-aquaporin-4 (AQP4) autoantibody-positive neuromyelitis optica spectrum disorder (NMOSD). Moreover, Alexion announced that it has entered into a definitive agreement for the company to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical and medicinal device organization that creates, develops, and showcases an expansive scope of prescription and non-prescription pharmaceutical products that have an important effect on patients' lives all through more than 100 nations. Valeant's essential focus is in the areas of dermatology and eye health.